The impact of lipid-lowering medications on coronary artery plaque characteristics.
The impact of lipid-lowering medications on coronary artery plaque characteristics.
复制标题
DOI:
10.1016/j.ajpc.2021.100294
复制
发表时间:
2021-12
影响因子:
4.1
通讯作者:
Alenghat FJ
中科院分区:
文献类型:
--
作者:
Pulipati VP;Alenghat FJ
Atherosclerosis is the predominant cause of coronary artery disease. The last several decades have witnessed significant advances in lipid-lowering therapies, which comprise a central component of atherosclerotic cardiovascular disease prevention. In addition to cardiovascular risk reduction with dyslipidemia management, some lipid-based therapies show promise at the level of the atherosclerotic plaque itself through mechanisms governing lipid accumulation, plaque stability, local inflammation, endothelial dysfunction, and thrombogenicity. The capacity of lipid-lowering therapies to modify atherosclerotic plaque burden, size, composition, and vulnerability should correlate with their ability to reduce disease progression. This review discusses plaque characteristics, diagnostic modalities to evaluate these characteristics, and how they are altered by current and emerging lipid-lowering therapies, all in human coronary artery disease.
登录
查看更多内容
影响因子:
4
作者:
Gibson MS;Domingues N;Vieira OV
通讯作者:
Vieira OV
影响因子:
9.3
作者:
Banach M;Serban C;Sahebkar A;Mikhailidis DP;Ursoniu S;Ray KK;Rysz J;Toth PP;Muntner P;Mosteoru S;García-García HM;Hovingh GK;Kastelein JJ;Serruys PW;Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group
通讯作者:
Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group
影响因子:
2.8
作者:
Kamanna, Vaijinath S.;Kashyap, Moti L.
通讯作者:
Kashyap, Moti L.
影响因子:
14
作者:
Hattori, Kousuke;Ozaki, Yukio;Narula, Jagat
通讯作者:
Narula, Jagat
影响因子:
14
作者:
Hamdan, Ashraf;Asbach, Patrick;Fleck, Eckart
通讯作者:
Fleck, Eckart